Bruckner-Tuderman L, Traupe H, Krieg T
Universitäts-Hautklinik Freiburg, BRD.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007 Dec;50(12):1541-7. doi: 10.1007/s00103-007-0389-1.
In Germany a disease is considered to be "rare" when its prevalence is less than 5:10,000. However, as far as genetic skin diseases are concerned, they are often much more uncommon with a prevalence in the range of 1:100,000. Currently considerable deficits prevail in both diagnosis and treatment of rare skin diseases. Driven by scientific research on rare skin diseases and benefiting from start-up grants of the Federal Ministry for Education and Research (BMBF), the following networks for rare skin diseases were formed: a) epidermolysis bullosa, b) ichthyosis and related keratinisation disorders, c) systemic scleroderma. From a scientific point of view these networks are very successful, they publish in high impact journals and at the same time developed into national centres of reference for the respective disease groups, although formally this status does not exist in Germany. Thus, the 5 year start-up grants considerably improved the clinical care for these three skin disease groups. However, now we are confronted with the threat that the newly formed structures will be difficult to maintain, due to lack of adequate financing. In contrast to France, Germany does not have a "national plan for rare diseases"--probably because the federal structure in Germany is difficult to reconcile with "national plans". In France the situation of clinical care for rare diseases is permanently restructured by the establishment of official national reference centres and by allocation of additional financial means to fulfill these national tasks. In our view, a similar approach is also necessary in Germany.
在德国,当一种疾病的患病率低于5:10,000时,就被视为“罕见病”。然而,就遗传性皮肤病而言,它们往往更为罕见,患病率在1:100,000范围内。目前,罕见皮肤病的诊断和治疗都存在相当大的不足。在对罕见皮肤病的科学研究推动下,并受益于联邦教育与研究部(BMBF)的启动资金,形成了以下罕见皮肤病网络:a)大疱性表皮松解症,b)鱼鳞病及相关角化障碍,c)系统性硬化症。从科学角度来看,这些网络非常成功,它们在高影响力期刊上发表论文,同时发展成为各自疾病组的国家参考中心,尽管在德国正式层面上不存在这种地位。因此,为期5年的启动资金极大地改善了这三个皮肤病组的临床护理。然而,现在我们面临着新形成的结构因缺乏足够资金而难以维持的威胁。与法国不同,德国没有“罕见病国家计划”——可能是因为德国的联邦结构难以与“国家计划”相协调。在法国,通过设立官方国家参考中心以及分配额外财政资源来完成这些国家任务,罕见病的临床护理状况在不断进行调整。我们认为,德国也有必要采取类似的方法。